Navigation Links
Human Genome Sciences Reports Growing Evidence That Its TRAIL,Receptor Antibodies Have Significant Potential in the Treatment of,a Broad Range of Cancers

- Journal of Clinical Oncology publishes first clinical study of HGS-ETR1 -

ROCKVILLE, Md., April 27, 2007 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. today reported that clinical and preclinical evidence continues to emerge demonstrating that its TRAIL receptor antibodies, HGS-ETR1 (mapatumumab) and HGS-ETR2 (lexatumumab), have significant potential for use in the treatment of a broad range of cancers.

"We believe that HGS-ETR1 and HGS-ETR2 could offer novel, highly targeted therapeutic options that may prove useful in the treatment of a number of cancers," said Gilles Gallant, B. Pharm., Ph.D., Vice President, Clinical Research - Oncology, HGS. "We note with pride that the Journal of Clinical Oncology, one of the field's most prestigious peer-reviewed publications, chose to publish the first human study of HGS-ETR1 earlier this month with an accompanying editorial - and, last week at AACR 2007, approximately 1500 cancer scientists and researchers attended our oral presentation of research results to date."

Results in the Journal of Clinical Oncology

The results of the first Phase 1 clinical trial of mapatumumab (HGS-ETR1) appeared in the April 10 issue of the Journal of Clinical Oncology (JCO), the official journal of the American Society of Clinical Oncology (ASCO). These results in 49 patients demonstrated that mapatumumab could be administered safely and repetitively to patients with advanced solid malignancies. The authors concluded that the absence of severe toxicities, and mapatumumab's ability to achieve blood levels consistent with antitumor activity in laboratory models, warrant further study of mapatumumab as a single agent and in combination with chemotherapy in a broad array of tumors.

Based on the initial Phase 1 results, along with extensive preclinical data, HGS initiated a broad clinical development program that included Phase 2 trials of HGS-ETR1 as a sin
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Testing for Human Papillomavirus
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
4. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
5. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
8. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
9. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
10. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
(Date:1/15/2014)...  A novel wearable injector slightly larger than an Oreo cookie ... self-inject prescription drugs in the large doses required to treat ... deficiencies, and genetic disorders.  An emerging biologic ... according to analysts.   Many of these drugs will require a ...
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... report results for the fourth quarter of 2013 on Monday, ... scheduled for release after the close of trading. ... a conference call to discuss the operating highlights and financial ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... YORK, June 8, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0487169/Novo-Nordisk-A/S-PharmaVitae-Profile.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory ... the historical and forecast performance for Novo ...
... 2011 Reportlinker.com announces that a ... in its catalogue: ... Analysis, Competitive Landscape and Market Forecasts ... http://www.reportlinker.com/p0548450/Hip-Replacement-Implants---Global-Pipeline-Analysis-Competitive-Landscape-and-Market-Forecasts-to-2017.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory Hip Replacement ...
Cached Medicine Technology:Novo Nordisk A/S: PharmaVitae Profile 2Reportlinker Adds Hip Replacement Implants - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 2Reportlinker Adds Hip Replacement Implants - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 3
(Date:4/17/2014)... San Diego School of Medicine report that older women, ... major loss are more likely to be compassionate toward ... published in this month,s issue of the International ... are associated with better health and well-being as we ... improve the outcomes of individuals whose deficits in compassion ...
(Date:4/17/2014)... Jon McCullers, MD, was recently invited to submit ... Nature Reviews Microbiology , one of the world,s ... infectious disease specialist, and chair of the Department ... Science Center, analyzed the epidemiology and microbiology of ... as well as more recent 2009 novel H1N1 ...
(Date:4/17/2014)... 2014) Doctors who treat patients with a ... can face an agonizing treatment decision. , The ... and help relieve shortness of breath. But some ... can cause potentially fatal complications following transplantation. , ... Dilling, medical director of Loyola University Medical Center,s ...
(Date:4/17/2014)... 2014-- Colic affects about one in five infants in ... visits during the first several months after birth. Research ... showing promise; however, the April 1, 2014 issue of ... reported on a study, "Probiotics and Infant Colic," concluding ... for infant colic did not reduce crying ...
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit organization ... published a comprehensive review today examining the current state ... The review calls for improved global surveillance strategies to ... recent outbreak of Ebola in West Africa that has ... of Guinea and Liberia. According to the World ...
Breaking Medicine News(10 mins):Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3
... can prevent the spread of melanoma// and other forms of ... a chemical found in turmeric, can block a biological pathway ... The chemical in the spices inhibits a protein called nuclear ... abnormal inflammations that can lead to a number of disorders ...
... vegetables and foods high in fibre can significantly// lower cholesterol ... ,Western cuisines are not so high in fibre and so ... ,10 healthy individuals were taken as the experimental group. ... diets were a vegetarian diet rich in fruits, vegetables and ...
... Expression of gene may be responsible for various immune ... the genes that cause two different form of immune ... Variable Immunodeficiency (CVID). ,Immune deficiency syndrome may be ... are generally caused by defects in the cells and ...
... or Vitamin B9 has been known to help in the ... now. Due to this reason it is administered to pregnant ... Netherlands has proposed that this vitamin can slow down the ... long study involved 818 subjects (both men and women) with ...
... on their genetic makeup, says a new study.// ... the same way even if they live a lifestyle totally ... Berkeley National Laboratory had looked into the health record of ... had a more sedentary life than another., ,The ...
... randomized trial published in Lancet Oncology, laparoscopic surgery// could ... the right, left, and sigmoid colon. The multicenter COLOR ... the short-term benefits of laparoscopic colectomy for cancer as ... been assigned to laparoscopic surgery and 621 patients to ...
Cached Medicine News:Health News:Fibre Rich Food A Boon For Lowering Cholesterol 2
With Skyscape's smARTlink technology, Tabers can cross-index with other clinical and drug prescription products from Skyscape to provide an integrated source of clinical information....
... This Mobile Solution (Palm OS) makes ... patient visit information functionality of the ... (PDA). You'll save time and have access ... at your desktop - review appointment schedules, ...
MD Coder Charge Capture Pocket PC Edition is a charge capture tool. We have integrated the feedback from hospitals and physicians. MD Coder Charge Capture supports both the Palm OS and Pocket PC plat...
... Management guidelines in selecting billing codes. As you ... the HCFA scores for each area and proper ... changing different parts of the exam. ZapCode can ... create an audit trail of your exam. It ...
Medicine Products: